| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1
* Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada;
Department of Biology,
Department of Physics, University of Colorado at Colorado Springs, Colorado Springs, Colorado, USA;
Division of Immunobiology,
# Division of Endocrinology, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA;
Immune Response Corporation, San Diego, California, USA;
|| Toronto Western Research Institute and Department of Physiology, University of Toronto, Toronto, Ontario;
¶ Department of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, Vermont, USA; and
** Colorado Associates in Medical Physics, Colorado Springs, Colorado, USA
1Correspondence: Department of Biology, 134 Science Bldg., 1420 Austin Bluffs Pkwy., University of Colorado at Colorado Springs, Colorado Springs, CO 80918, USA. E-mail: mnewell{at}mail.uccs.edu
Acquired or inherent drug resistance is the major problem in achieving successful cancer treatment. However, the mechanism(s) of pleiotropic drug resistance remains obscure. We have identified and characterized a cellular metabolic strategy that differentiates drug-resistant cells from drug-sensitive cells. This strategy may serve to protect drug-resistant cells from damage caused by chemotherapeutic agents and radiation. We show that drug-resistant cells have low mitochondrial membrane potential, use nonglucose carbon sources (fatty acids) for mitochondrial oxygen consumption when glucose becomes limited, and are protected from exogenous stress such as radiation. In addition, drug-resistant cells express high levels of mitochondrial uncoupling protein 2 (UCP2). The discovery of this metabolic strategy potentially facilitates the design of novel therapeutic approaches to drug resistance.—Harper, M.-E., Antoniou, A., Villalobos-Menuey, E., Russo, A., Trauger, R., Vendemelio, George, A. M., Bartholomew, R., Carlo, D., Shaikh, A., Kupperman, J., Newell, E. W., Bespalov, I. A., Wallace, S. S., Liu, Y., Rogers, J. R., Gibbs, G. L., Leahy, J. L., Camley, R. E., Melamede, R., Newell, M. K. Characterization of a novel metabolic strategy used by drug-resistant tumor cells.
Key Words: cancer • mitochondria • uncoupling proteins • membrane potential • oxygen consumption
This article has been cited by other articles:
|
|
 |
|
  A. Anedda, E. Rial, and M M. Gonzalez-Barroso Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels J. Endocrinol., October 1, 2008; 199(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Liang, T. Finkel, D.-W. Shen, J.-J. Yin, A. Aszalos, and M. M. Gottesman SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism Mol. Cancer Res., September 1, 2008; 6(9): 1499 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Samudio, M. Fiegl, T. McQueen, K. Clise-Dwyer, and M. Andreeff The Warburg Effect in Leukemia-Stroma Cocultures Is Mediated by Mitochondrial Uncoupling Associated with Uncoupling Protein 2 Activation Cancer Res., July 1, 2008; 68(13): 5198 - 5205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Derdak, N. M. Mark, G. Beldi, S. C. Robson, J. R. Wands, and G. Baffy The Mitochondrial Uncoupling Protein-2 Promotes Chemoresistance in Cancer Cells Cancer Res., April 15, 2008; 68(8): 2813 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Pan and T. W. Mak Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? Sci. Signal., April 10, 2007; 2007(381): pe14 - pe14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Derdak, P. Fulop, E. Sabo, R. Tavares, E. P. Berthiaume, M. B. Resnick, G. Paragh, J. R. Wands, and G. Baffy Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-{kappa}B activation and oxidative stress Carcinogenesis, May 1, 2006; 27(5): 956 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qian, M. Nishikawa, A. Md. Haque, M. Hirose, M. Mashimo, E. Sato, and M. Inoue Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1466 - C1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. MacLellan, M. F. Gerrits, A. Gowing, P. J.S. Smith, M. B. Wheeler, and M.-E. Harper Physiological Increases in Uncoupling Protein 3 Augment Fatty Acid Oxidation and Decrease Reactive Oxygen Species Production Without Uncoupling Respiration in Muscle Cells Diabetes, August 1, 2005; 54(8): 2343 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Karawajew, P. Rhein, G. Czerwony, and W.-D. Ludwig Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species Blood, June 15, 2005; 105(12): 4767 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Horimoto, M. B. Resnick, T. A. Konkin, J. Routhier, J. R. Wands, and G. Baffy Expression of Uncoupling Protein-2 in Human Colon Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6203 - 6207. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
